Core Insights - Tempus AI (TEM) is set to release its fourth-quarter 2025 results on February 24, 2026, after market close, with expectations of strengthened performance in 2026 due to strategic collaborations and product innovations [1] Financial Performance - Preliminary results indicate that revenues for the full year 2025 reached approximately $1.27 billion, marking an 83% year-over-year increase, with about 30% of this growth being organic [2] - Diagnostics revenues totaled around $955 million, reflecting a 111% year-over-year increase, driven by a 26% growth in oncology volume and a 29% increase in hereditary testing volume [3] - Data and applications revenues reached approximately $316 million, showing a 31% year-over-year growth, partly due to a 38% improvement in the Insights (data licensing) business [3][4] - The company achieved a Total Contract Value (TCV) of over $1.1 billion as of December 31, 2025, and reported positive adjusted EBITDA of $1.5 million in Q3 2025, a year-over-year improvement of $23.3 million [12] Strategic Collaborations - Tempus has entered a multi-year collaboration with Whitehawk Therapeutics, leveraging its proprietary dataset to enhance oncology research and clinical trial design [7][8] - The company initiated a research study with the Institute for Follicular Lymphoma Innovation, marking its first collaboration with a nonprofit to create a robust dataset for follicular lymphoma [11] Market Position and Challenges - Despite significant revenue growth, Tempus' stock price has declined by 32.9% in Q4, reflecting a broader negative sentiment in the AI medtech sector [6] - The stock currently trades at a price-to-book (P/B) ratio of 17.79X, which is above the industry average of 8.76X, raising valuation concerns [10][20] - The company continues to face challenges with GAAP losses due to stock-based compensation and amortization of acquired intangibles, limiting visibility into sustainable profitability [17][18] Future Outlook - The company is positioned as a high-growth leader at the intersection of AI and precision medicine, with strong operational momentum expected to continue into 2026 [21] - Investors are advised to maintain their positions in Tempus stock, which is currently rated as a Zacks Rank 4 (Sell) [22]

Azenta logo 5 medical stocks growing earnings by triple digits Azenta (NASDAQ:AZTA) reported fiscal first-quarter 2026 revenue of $149 million, up 1% on a reported basis but down 1% organically, as continued macro uncertainty and cautious capital spending weighed on parts of its portfolio. Management reaffirmed full-year guidance calling for 3% to 5% organic revenue growth and roughly 300 basis points of adjusted EBITDA margin expansion, while acknowledging that the turnaround “will not be a straight ...

Core Viewpoint - Azenta's affiliate, Azenta Germany, has signed a binding agreement to sell its B Medical Systems business to THELEMA S.A R.L. for a purchase price of $63 million, with the transaction expected to close on or before March 31, 2026 [1] Group 1 - The sale of B Medical Systems is aimed at simplifying Azenta's portfolio to focus on core capabilities that have the highest strategic impact [1] - The proceeds from the sale will be used to strengthen the company and drive long-term profitable value creation for shareholders [1]

Group 1 - Alamo Group Inc. (ALG) designs and manufactures high-quality agricultural equipment and provides infrastructure maintenance, with a nearly 10% downward revision in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - Azenta, Inc. (AZTA) offers life sciences solutions, including sample management and laboratory automation, experiencing an 11.8% downward revision in the Zacks Consensus Estimate for its current year earnings over the last 60 days [2] - Chipotle Mexican Grill, Inc. (CMG) is a restaurant chain that has seen a 2.5% downward revision in the Zacks Consensus Estimate for its current year earnings over the last 60 days [2]

Core Insights - Azenta and SOPHiA GENETICS are compared based on various financial metrics and market performance indicators to determine which company is superior in the medical sector Volatility and Risk - Azenta has a beta of 1.29, indicating its share price is 29% more volatile than the S&P 500 - SOPHiA GENETICS has a beta of 1.1, suggesting its share price is 10% more volatile than the S&P 500 [1][2] Institutional & Insider Ownership - 99.1% of Azenta shares are owned by institutional investors, while 31.6% of SOPHiA GENETICS shares are owned by institutional investors - 10.6% of Azenta shares are owned by company insiders, compared to 4.9% for SOPHiA GENETICS [2] Profitability - Azenta's net margin is -10.01%, return on equity is 1.40%, and return on assets is 1.17% - SOPHiA GENETICS has a net margin of -41.13%, return on equity of -37.75%, and return on assets of -18.75% [4] Earnings and Valuation - Azenta's gross revenue is $593.82 million with a price/sales ratio of 2.71, while SOPHiA GENETICS has a gross revenue of $65.17 million and a price/sales ratio of 5.03 - Azenta's net income is -$59.50 million with an earnings per share of -$1.30 and a price/earnings ratio of -26.96 - SOPHiA GENETICS has a net income of -$62.49 million with an earnings per share of -$0.46 and a price/earnings ratio of -10.54 - Azenta has higher revenue and earnings than SOPHiA GENETICS and is trading at a lower price-to-earnings ratio, indicating it is more affordable [6] Analyst Recommendations - Azenta has 2 sell ratings, 3 hold ratings, and 3 buy ratings, resulting in a rating score of 2.13 - SOPHiA GENETICS has 1 sell rating, 0 hold ratings, and 2 buy ratings, resulting in a rating score of 2.33 - Azenta's consensus price target is $38.60, suggesting a potential upside of 10.13%, while SOPHiA GENETICS has a consensus price target of $9.00, suggesting a potential upside of 85.57% [8] Summary - Azenta outperforms SOPHiA GENETICS in 9 out of 14 factors compared between the two companies [9]

Market Overview - Stocks and bonds received support from dovish comments by New York Fed President John Williams, indicating potential adjustments to the federal funds rate to align with neutral policy [1] - The S&P 500 Index closed up by +0.98%, the Dow Jones Industrials Index by +1.08%, and the Nasdaq 100 Index by +0.77% [5] - Semiconductor stocks led the market rally, with notable gains from companies like GlobalFoundries (+5%) and ON Semiconductor (+4%) [15] Economic Indicators - The University of Michigan's November 1-year inflation expectations were revised lower to 4.5% from 4.7%, and the 5-10 year expectations were revised to 3.4% from 3.6% [2] - The consumer sentiment index for November was revised upward by +0.7 to 51.0, surpassing expectations of 50.6 [2] - The S&P manufacturing PMI for November fell -0.6 to 51.9, close to expectations of 52.0 [2] Corporate Earnings - Q3 earnings season is concluding, with 82% of S&P 500 companies exceeding forecasts, resulting in a +14.6% increase in earnings, significantly above the expected +7.2% [8] - Azenta Inc reported Q4 revenue of $159 million, exceeding the consensus of $156.4 million, leading to a +16% stock increase [17] - Ross Stores reported Q3 sales of $5.60 billion, stronger than the consensus of $5.41 billion, resulting in an +8% stock increase [17] Sector Performance - Home builders and building suppliers saw gains due to falling 10-year T-note yields, with Builders FirstSource closing up more than +7% [14] - Defense stocks retreated following news of a peace plan in Ukraine, with L3Harris Technologies down more than -2% [16] - Chip makers experienced a recovery, contributing to the overall market rise, with several companies closing up more than +3% [15] International Markets - Overseas stock markets closed lower, with the Euro Stoxx 50 down -0.98% and China's Shanghai Composite down -2.45% [9]

Market Overview - The U.S. stock market experienced a significant rebound on November 21, 2025, with major indexes closing higher, recovering from earlier losses driven by optimism regarding potential interest rate cuts by the Federal Reserve [1][4] - The Dow Jones Industrial Average (DJI) rose 1.4%, adding 650 points, while the S&P 500 (SPX) gained 1.4%, closing at 6,590 points, and the Nasdaq Composite (IXIC) increased by 1.5% [2] Federal Reserve Influence - New York Federal Reserve President John Williams indicated support for a potential interest rate cut "in the near term," which shifted market expectations significantly, raising the likelihood of a rate cut at the December meeting to 73.1% from 39.1% [4] Corporate Performance - Nvidia (NVDA) reported a 62% year-over-year revenue increase to $57 billion, but its shares fell 3.2% on Thursday and 1.7% on Friday due to concerns over AI valuations [5] - Walmart (WMT) saw its stock decline by approximately 2% on Friday after a strong performance on Thursday, where it had jumped 6.5% following better-than-expected third-quarter results [6] - Retailers like Gap (GPS) and Ross Stores (ROST) had positive performances, with Gap surging 9.5% and Ross jumping 8.5% due to strong earnings [7] Notable Stock Movements - Alphabet (GOOGL) increased by over 3%, while Meta Platforms (META) added 1%. In contrast, Microsoft (MSFT) shares fell approximately 1%, and Oracle (ORCL) slid more than 4% [8] Upcoming Earnings and Economic Data - Several companies, including BJ's Wholesale Club Holdings (BJ) and IES Holdings (IESC), reported earnings after the market closed, with BJ's EPS at $1.16 against a forecast of $1.10 [9][10] - The upcoming week will feature key economic data releases, including the Producer Price Index (PPI) and Retail Sales for September, which were delayed due to a government shutdown [12]

Economic Indicators - The University of Michigan's US Nov 1-year inflation expectations were revised lower to 4.5% from 4.7% and the Nov 5-10 year inflation expectations were revised lower to 3.4% from 3.6% [2] - The US Nov consumer sentiment index was revised upward by +0.7 to 51.0, stronger than expectations of 50.6 [2] - The US Nov S&P manufacturing PMI fell -0.6 to 51.9, close to expectations of 52.0 [2] Stock Market Performance - US stock indexes were mixed early but extended gains in the afternoon, with the S&P 500 Index up by +1.38%, the Dow Jones up by +1.52%, and the Nasdaq 100 up by +1.14% [5] - Stock indexes initially moved higher due to comments from New York Fed President John Williams, which increased the chance of a Fed rate cut at the next FOMC meeting to 70% from 35% [3][7] Corporate Earnings - Q3 corporate earnings season is concluding, with 82% of reporting S&P 500 companies exceeding forecasts, leading to a +14.6% increase in earnings, more than doubling expectations of +7.2% y/y [8] - Home builders and building suppliers saw gains as the 10-year T-note yield fell to a 3-week low, with companies like DR Horton up more than +5% [14] Cryptocurrency Market - The price of Bitcoin fell by more than -2% to a 7.25-month low, continuing a sharp 6-week downtrend with prices down more than 35% from a record high last month [6] - Cryptocurrency-exposed stocks faced pressure, with notable declines in companies like Strategy down more than -6% and Galaxy Digital Holdings down more than -5% [16] International Markets - Overseas stock markets were lower, with the Euro Stoxx 50 down -0.95%, China's Shanghai Composite down -2.45%, and Japan's Nikkei Stock 225 down -2.40% [9][12]

Group 1: Ross Stores Inc - Ross Stores reported third-quarter earnings of $1.58 per share, exceeding the analyst estimate of $1.41 [1] - Quarterly revenue for Ross Stores was $5.6 billion, surpassing the analyst consensus estimate of $5.42 billion [1] - The company raised its FY25 GAAP EPS guidance above estimates, contributing to a sharp rise in its stock price [1] Group 2: Stock Performance - Ross Stores shares increased by 6.3% to $170.64 following the earnings report [2] - Other notable stock gains included Enviri Corp, which saw a 29.1% increase to $17.51 after announcing a $3.04 billion sale [4] - Several companies recorded significant stock price increases, including Herbalife Ltd (up 11.6% to $10.76) and Quidelortho Corp (up 10.1% to $23.46) [4]

Core Insights - Outset Medical, Inc. reported a quarterly loss of $0.69 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.64, marking an earnings surprise of -7.81% [1] - The company's revenues for the quarter ended September 2025 were $29.43 million, missing the Zacks Consensus Estimate by 3.19%, but showing an increase from $28.67 million year-over-year [2] - Outset Medical shares have declined approximately 27.5% year-to-date, contrasting with the S&P 500's gain of 14.4% [3] Financial Performance - Over the last four quarters, Outset Medical has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] - The current consensus EPS estimate for the upcoming quarter is -$0.54 on revenues of $32.4 million, and for the current fiscal year, it is -$3.96 on revenues of $124 million [7] Market Outlook - The company's stock performance in the near future is expected to align with the market, as indicated by a Zacks Rank 3 (Hold) [6] - The outlook for the Medical Info Systems industry, where Outset Medical operates, is relatively strong, ranking in the top 27% of over 250 Zacks industries [8]